HomeNewsCronus pharma

Cronus Pharma

Jump to

Aurobindo Pharma’s Cronus rethink is positive, but it needs to do more

Aurobindo Pharma terminated an agreement to acquire a majority stake in Cronus Pharma after the proposal stoked capital allocation concerns
Aurobindo Pharma: Termination of inorganic bet eases capital allocation worries

We believe termination of the Cronus Pharma acquisition deal should help remove corporate governance/capital allocation fears
Aurobindo Pharma says Rs 450-crore deal to acquire 51% in Cronus Pharma cancelled

In a regulatory filing on Friday, Aurobindo Pharma said, 'The board of directors in its meeting held today has approved the termination of the aforesaid agreements, and the parties have mutually agreed and terminated the said agreements.'

Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their investments. We wish to reiterate that Moneycontrol does not solicit funds from investors and neither does it promise any assured returns. In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347

Cronus Pharma

Aurobindo Pharma’s Cronus rethink is positive, but it needs to do more

Aurobindo Pharma: Termination of inorganic bet eases capital allocation worries

Aurobindo Pharma says Rs 450-crore deal to acquire 51% in Cronus Pharma cancelled